Added to YB: 2025-02-11
Pitch date: 2025-02-10
NKTR [bullish]
Nektar Therapeutics
+417.26%
current return
Author Info
No bio for this author
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Market Cap
$1.1B
Pitch Price
$10.57
Price Target
7.00 (-87%)
Dividend
N/A
EV/EBITDA
-7.95
P/E
-6.87
EV/Sales
15.99
Sector
Pharmaceuticals
Category
special_situation
NKTR: A Deep Value Play with Major Upside Potential
NKTR: Trading at 0.45x cash, Q2 AD readout could be game-changer. P1b data promising: 43% EASI75 delta at Wk10. Potential for Q12W dosing. Even moderate efficacy valuable given comps. Severe undervaluation vs peers pre-readout (QTTB, ANAB, CRVS). High risk/reward.
Read full article (6 min)